Market Place
Sourcing Support
Neurosense Granted Brazilian Patent Covering Primec Composition
06 Apr 2026 //
PR NEWSWIRE
NeuroSense Therapeutics Secures Nasdaq Bid, Shares Surge
03 Apr 2026 //
PR NEWSWIRE
NeuroSense Therapeutics Reports 2025 Results, Business Update
31 Mar 2026 //
PR NEWSWIRE
NeuroSense Advances Toward Key Alzheimer’s Readout
24 Mar 2026 //
PR NEWSWIRE
Primec Shows Promising Results In ALS Trial Published By JAMA
16 Mar 2026 //
PR NEWSWIRE
Primec To Present Long-Term Survival Data At ALS Conference
09 Mar 2026 //
PR NEWSWIRE
Neurosense Reveals Primec`s 65% Death Risk Cut In ALS
18 Feb 2026 //
PR NEWSWIRE
Neurosense Enhances Global IP Strategy With Australian Patent
09 Feb 2026 //
PR NEWSWIRE BIO
Neurosense Receives U.S. Patent For Alzheimer`s Disease Treatment
21 Jan 2026 //
PR NEWSWIRE
Prof. Steven Arnold Joins Neurosense Scientific Advisory Board
08 Jan 2026 //
PR NEWSWIRE
Neurosense Reports Primec`s Safe Use In Alzheimer`s Ph2 Study
22 Dec 2025 //
PR NEWSWIRE BIO
Neurosense Plans Pre-NDS Meeting With Health Canada In April 2026
04 Dec 2025 //
PR NEWSWIRE
Neurosense Cleared For Primec Phase 3 Trial In ALS
24 Nov 2025 //
PR NEWSWIRE
Neurosense`s Primec Shows Significant Alzheimer`s Biomarker
06 Oct 2025 //
PR NEWSWIRE
NeuroSense`s Drug Shows Early Benefit in Alzheimer`s Neurons
10 Sep 2025 //
PR NEWSWIRE
NeuroSense Updates on Business Progress in First Half of 2025
01 Aug 2025 //
PR NEWSWIRE
Aaron Lazar and NeuroSense CEO Alon Ben-Noon discuss ALS science
22 Jul 2025 //
PR NEWSWIRE
NeuroSense Completes PrimeC Scale-Up for Canada Launch
07 May 2025 //
PR NEWSWIRE
NeuroSense Therapeutics Updates Shareholders on Clinical Progress
24 Apr 2025 //
PR NEWSWIRE
NeuroSense Therapeutics to Present Data from PrimeC at AAN Meeting
04 Apr 2025 //
PR NEWSWIRE
NeuroSense Regains Compliance With Nasdaq Minimum Equity Rules
06 Jan 2025 //
PR NEWSWIRE
NeuroSense Enters Term Sheet to Advance PrimeC for ALS
23 Dec 2024 //
PR NEWSWIRE
NeuroSense Gets FDA Support For PrimeC Phase 3 Trial Design
11 Dec 2024 //
PR NEWSWIRE
NeuroSense PARADIGM Study Highlights PrimeC Benefits In ALS
04 Dec 2024 //
PR NEWSWIRE
NeuroSense Therapeutics to Present at ALS/MND Symposium 2024
21 Nov 2024 //
PR NEWSWIRE
NeuroSense Advances Phase 3 ALS Trial and NDA Submission
28 Oct 2024 //
PR NEWSWIRE
New Analysis Shows PrimeC Improves miRNAs In ALS Patients
24 Oct 2024 //
PR NEWSWIRE
NeuroSense Advances Plans For ALS Treatment Commercialization
15 Oct 2024 //
PR NEWSWIRE
NeuroSense Plans To File For Early Commercialization In Canada
09 Oct 2024 //
PR NEWSWIRE
NeuroSense Announces Acceptance Of Two PrimeC Abstracts At NEALS 2024
07 Oct 2024 //
PR NEWSWIRE
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
24 Sep 2024 //
PR NEWSWIRE
NeuroSense Granted Key U.S. Patent for PrimeC in ALS, Alzheimer`s
24 Sep 2024 //
PR NEWSWIRE
NeuroSense Therapeutics Receives Nasdaq Minimum Bid Price Notification
30 Aug 2024 //
PR NEWSWIRE
NeuroSense Therapeutics Announces Private Placement At Premium
07 Aug 2024 //
PR NEWSWIRE
NeuroSense Reports Positive ALS Phase 2b Biomarker Data
01 Aug 2024 //
PR NEWSWIRE
NeuroSense, Lonza Partner On Exosome Biomarkers, Neurodegeneration
09 Apr 2024 //
PR NEWSWIRE
On lookout for ALS biomarker, Biogen pens Israeli biotech pact
15 Jun 2023 //
FIERCE BIOTECH
NeuroSense Reports Positive Preliminary Results in Parkinson`s Biomarker Study
02 May 2023 //
PR NEWSWIRE
NeuroSense & Massachusetts General Hospital`s NeuroEpigenetics to Collaborate
27 Mar 2023 //
PR NEWSWIRE
